Literature DB >> 20851166

Neuromelanin inhibits CXCL10 expression in human astroglial cells.

Neda Saffarian Tousi1, Daniel J Buck, Luigi Zecca, Randall L Davis.   

Abstract

Increasing evidence indicates neuroinflammation is instrumental in the pathogenesis of Parkinson's disease (PD). In PD, there is selective degeneration of neuromelanin (NM)-containing dopamine neurons. Neuromelanin is predominantly cytoprotective within dopaminergic neurons, whereas, NM released from damaged neurons activates microglia. However, the effects of NM on astroglial cells remain largely unknown. Astroglia are essential to neuronal homeostasis and responsive to injury, in part, through secretion of chemokines, including interferon γ inducible protein-10 (CXCL10). Thus, we used an in vitro approach to identify the effects of NM on TNFα-induced CXCL10 expression in human astroglial cells. TNFα-induced CXCL10 expression was inhibited in NM exposed cells. Additionally, TNFα-induced NF-кB activation was inhibited by NM. Given that CXCL10 expression is NF-кB-dependent in human astroglial cells, these findings suggest that NM may inhibit CXCL10 expression, in part, through an NF-кB-dependent mechanism. While the in vivo consequences of NM mediated effects on astroglial CXCL10 expression remain to be fully elucidated, insights obtained in this study further our understanding of the effects of NM on inflammatory signaling in human astroglial cells.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851166      PMCID: PMC2987750          DOI: 10.1016/j.neulet.2010.09.042

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  50 in total

1.  Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity.

Authors:  A M Cole; T Ganz; A M Liese; M D Burdick; L Liu; R M Strieter
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

Review 2.  Glial cell influence on the human blood-brain barrier.

Authors:  A Prat; K Biernacki; K Wosik; J P Antel
Journal:  Glia       Date:  2001-11       Impact factor: 7.452

Review 3.  Changes in cytokines and neurotrophins in Parkinson's disease.

Authors:  T Nagatsu; M Mogi; H Ichinose; A Togari
Journal:  J Neural Transm Suppl       Date:  2000

4.  Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease.

Authors:  Wei Zhang; Kester Phillips; Albert R Wielgus; Jie Liu; Alberto Albertini; Fabio A Zucca; Rudolph Faust; Steven Y Qian; David S Miller; Colin F Chignell; Belinda Wilson; Vernice Jackson-Lewis; Serge Przedborski; Danielle Joset; John Loike; Jau-Shyong Hong; David Sulzer; Luigi Zecca
Journal:  Neurotox Res       Date:  2009-12-03       Impact factor: 3.911

5.  Ethanol-induced modulation of inducible nitric-oxide synthase activity in human A172 astrocytoma cells.

Authors:  Randall L Davis; Janet Dertien; Peter J Syapin
Journal:  Alcohol Clin Exp Res       Date:  2002-09       Impact factor: 3.455

Review 6.  Parkinsonism in HIV dementia.

Authors:  E Koutsilieri; S Sopper; C Scheller; V ter Meulen; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2002-05       Impact factor: 3.575

7.  Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes.

Authors:  L Zecca; M Gallorini; V Schünemann; A X Trautwein; M Gerlach; P Riederer; P Vezzoni; D Tampellini
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

8.  The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease.

Authors:  Luigi Zecca; Ruggero Fariello; Peter Riederer; David Sulzer; Alberto Gatti; Davide Tampellini
Journal:  FEBS Lett       Date:  2002-01-16       Impact factor: 4.124

9.  Interaction of human substantia nigra neuromelanin with lipids and peptides.

Authors:  L Zecca; P Costi; C Mecacci; S Ito; M Terreni; S Sonnino
Journal:  J Neurochem       Date:  2000-04       Impact factor: 5.372

10.  Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles.

Authors:  D Sulzer; J Bogulavsky; K E Larsen; G Behr; E Karatekin; M H Kleinman; N Turro; D Krantz; R H Edwards; L A Greene; L Zecca
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

View more
  6 in total

Review 1.  Neuromelanin of the human substantia nigra: an update.

Authors:  Fabio A Zucca; Emy Basso; Francesca A Cupaioli; Emanuele Ferrari; David Sulzer; Luigi Casella; Luigi Zecca
Journal:  Neurotox Res       Date:  2013-10-24       Impact factor: 3.911

2.  The opioid antagonist, β-funaltrexamine, inhibits NF-κB signaling and chemokine expression in human astrocytes and in mice.

Authors:  Randall L Davis; Subhas Das; J Thomas Curtis; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2015-05-22       Impact factor: 4.432

3.  α-Synuclein potentiates interleukin-1β-induced CXCL10 expression in human A172 astrocytoma cells.

Authors:  Neda Saffarian Tousi; Daniel J Buck; J Thomas Curtis; Randall L Davis
Journal:  Neurosci Lett       Date:  2011-12-13       Impact factor: 3.046

4.  Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes.

Authors:  Randall L Davis; Subhas Das; Daniel J Buck; Craig W Stevens
Journal:  Neurochem Int       Date:  2013-01-31       Impact factor: 3.921

Review 5.  The Neuromelanin Paradox and Its Dual Role in Oxidative Stress and Neurodegeneration.

Authors:  Alexandra Moreno-García; Alejandra Kun; Miguel Calero; Olga Calero
Journal:  Antioxidants (Basel)       Date:  2021-01-16

Review 6.  Interaction of Neuromelanin with Xenobiotics and Consequences for Neurodegeneration; Promising Experimental Models.

Authors:  Andrea Capucciati; Fabio A Zucca; Enrico Monzani; Luigi Zecca; Luigi Casella; Tim Hofer
Journal:  Antioxidants (Basel)       Date:  2021-05-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.